- Home
- PRAX vs LBTYA Comparison
PRAX vs LBTYA Comparison
Compare PRAX & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | LBTYA |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | LBTYA |
|---|---|---|
| Price | $267.06 | $11.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $304.43 | $14.77 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,463,000.00 | ★ $4,770,600,000.00 |
| Revenue This Year | N/A | $13.22 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 364.98 | 170.50 |
| 52 Week Low | $26.70 | $9.03 |
| 52 Week High | $278.44 | $13.17 |
Technical Indicators
Market Signals| Indicator | PRAX | LBTYA |
|---|---|---|
| Relative Strength Index (RSI) | 71.53 | 53.23 |
| Support Level | $251.00 | $10.76 |
| Resistance Level | $278.44 | $11.44 |
| Average True Range (ATR) | 17.08 | 0.28 |
| MACD | 6.49 | -0.00 |
| Stochastic Oscillator | 90.84 | 51.63 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.